CATXNYSEPharmaceutical PreparationsFiscal year ends December 31
Perspective Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$2.19+0.02 (+0.92%)
Close on Oct 19, 2026
- Market cap
- $264.23M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$2.30 (−51.22%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $264.23M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.82
- Dividend yield
- –
- Free cash flow yield
- -45.86%
Fundamentals
- Net income
- -$116.43M
- EPS, diluted
- -$1.32
- Free cash flow
- -$121.19M
- Book value per share
- $2.68
- Diluted shares
- 121M
Fifteen years at a glance
Fiscal years 2010 to 2025 and trailing twelve months, USD
Revenue
–
Gross profit
–
Operating income
-$125.23M
Net income
-$116.43M
EPS, diluted
-$1.32
Free cash flow
-$121.19M
Reported periodTrailing twelve months